You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
AstraZeneca
Medtronic
McKinsey
Harvard Business School

Last Updated: February 22, 2024

Lemborexant - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for lemborexant and what is the scope of patent protection?

Lemborexant is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Lemborexant has fifty-three patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for lemborexant
International Patents:53
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 42
Clinical Trials: 26
Patent Applications: 24
What excipients (inactive ingredients) are in lemborexant?lemborexant excipients list
DailyMed Link:lemborexant at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for lemborexant
Generic Entry Date for lemborexant*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for lemborexant

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Brendan LuceyPhase 2
Chulalongkorn UniversityPhase 1/Phase 2
Eisai Co., Ltd.Phase 2

See all lemborexant clinical trials

Pharmacology for lemborexant

US Patents and Regulatory Information for lemborexant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-001 Apr 7, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-001 Apr 7, 2020 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-002 Apr 7, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-002 Apr 7, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-002 Apr 7, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for lemborexant

Country Patent Number Title Estimated Expiration
China 103153963 Cyclopropane compound ⤷  Try a Trial
Croatia P20150657 ⤷  Try a Trial
Canada 2964504 FORME DE DOSE ORALE COMPRENANT UN DERIVE DE CYCLOPROPANECARBOXAMIDE POURUTILISATION DANS LE TRAITEMENT DE L'INSOMNIE (ORAL DOSAGE FORM COMPRISING A CYCLOPROPANECARBOXAMIDE DERIVATIVE FOR USE IN TREATING INSOMNIA) ⤷  Try a Trial
Serbia 54101 CIKLOPROPANSKO JEDINJENJE (CYCLOPROPANE COMPOUND) ⤷  Try a Trial
Tunisia 2013000119 CYCLOPROPANE COMPOUNDS ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Dow
Express Scripts
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.